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Abstract 
Background: Immunotherapy based on the adoptive transfer of gene modified T cells is an emerging approach 
for the induction of tumor‑specific immune responses. Memory stem T cells, due to their enhanced antitumor and 
self‑renewal capacity, have become potential candidate for adoptive T cell therapy of cancer. Methods to generate 
memory stem T cells ex vivo rely on CD3/CD28 costimulation and the use of cytokines such as IL‑7 and IL‑15 during 
the entire culture period. However, a strong costimulation may induce differentiation of memory stem T cells to effec‑
tor memory T cells. Here we show that manipulation of the length of the costimulation and addition of IL‑21 enhance 
the ex vivo expansion of memory stem T cells.
Methods: Purified naïve T cells from healthy donors were cultured in the presence of anti‑CD3/CD28 coated beads, 
IL‑7, IL‑15 and/or IL‑21 (25 ng/ml). T cells phenotype from the different memory and effector subpopulations were 
analyzed by multiparametric flow cytometry.
Results: A short anti‑CD3/CD28 costimulation of naïve T cells, combined with IL‑7 and IL‑15 significantly increased 
the frequencies of CD4+ and CD8+ memory stem T cells ex vivo, compared to a prolonged costimulation 
(34.6 ± 4.4 % vs 15.6 ± 4.24 % in CD4+; p = 0.008, and 20.5 ± 4.00 % vs 7.7 ± 2.53 % in CD8+; p = 0.02). Moreover, the 
addition of IL‑21 to this condition further enhanced the enrichment and expansion of CD4+ and CD8+ memory stem 
T cells with an increase in the absolute numbers (0.7 × 106 ± 0.1 vs 0.26 × 106 ± 0.1 cells for CD4+; p = 0.002 and 
1.1 × 106 ± 0.1 vs 0.27 × 106 ± 0.1 cells for CD8+; p = 0.0002; short + IL‑21 vs long).
Conclusions: These new in vitro conditions increase the frequencies and expansion of memory stem T cells and may 
have relevant clinical implications for the generation of this memory T cell subset for adoptive cell therapy of patients 
with cancer.
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Background
Adoptive T cell therapy (ACT) represents a highly prom-
ising strategy to treat cancer [1, 2]. While this approach 
has been mostly based on the use of terminally differ-
entiated effector T cells, recent studies indicate that 
the use of less differentiated T cells with extensive rep-
licative capacity has greater engraftment and antitumor 
effect [3–6]. In particular, the recently described mem-
ory stem T cells (TSCM), defined as CD62L+CCR7+CD
45RA+CD95+CD45RO−CD28+CD27+IL2Rb+IL7Rα+, 
have enhanced proliferation, self-renewal, persistence 
and are able to differentiate into central memory, effec-
tor memory and effector T cells [6, 7]. Remarkably, stud-
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antitumor effect in vivo compared to other more differ-
entiated T cell subsets [6, 8].
All these features make TSCM a promising T cell subset 
candidate for ACT of cancer. Although TSCM have been 
identified in the peripheral blood under basal conditions, 
the very low amount of these cells pose difficulty to their 
isolation, limiting their use for ACT of patients with can-
cer. Gattinoni et  al. showed that CD8+ TSCM could be 
generated through the induction of the Wnt-β-catenin 
signaling [6]. Further studies demonstrated the gen-
eration and expansion of CD8+ TSCM from naïve T cells 
[9–11] through CD3/CD28 costimulation in combina-
tion with IL-7 and IL-15 cytokines. However, prolonged 
in vitro costimulation decrease the expression of memory 
markers substantially (e.g., CD62L, CCR7 or CD27) lead-
ing to a swift to more differentiated T cells [12, 13]. For 
these reasons, identification of reproducible methods to 
generate and expand large numbers of TSCM for ACT of 
cancer remains a clinical priority.
IL-21, the most recent member of the common γ-chain 
(γc) receptor cytokine family (that includes IL-2, IL-7, 
and IL-15), has a role in innate and adaptive immunity 
[12], and contrary to IL-2, plays a key role in the devel-
opment and maintenance of central memory T cells by 
the induction of an early differentiation phenotype [14]. 
Importantly, T cells generated under IL-21 showed a 
superior antitumor effect in vivo in experimental models 
[15–17]. IL-21 acts synergistically with IL-7 and IL-15 to 
promote proliferation and survival of both memory and 
naïve T cells [18, 19]. However, to our knowledge the 
effects of IL-21 on the TSCM generation have not been 
studied so far.
We explored whether manipulating the length of CD3/
CD28 costimulation and/or the addition of IL-21 could 
enrich for the TSCM population within T cells cultured 
under IL-7 and IL-15. We found that both, a very short 
costimulation and the addition of IL-21 increase the fre-
quencies of CD4+ and CD8+ TSCM and enhance their 
proliferative capacity, resulting in a significant increase 
of TSCM numbers at the end of the culture. Our work 
reveals a new method to ex vivo enrich and expand TSCM, 
which may have relevant clinical implications for ACT of 
patients with cancer.
Methods
T‑cell isolation, sorting and culture
Peripheral blood mononuclear cells (PBMCs) were 
obtained from healthy donors (n = 6) after informed con-
sent, isolated by centrifugation through a ficoll-hypaque 
gradient (lymphoprep, Axis-shield, UK), and frozen until 
use. Naïve T-cells were enriched with an on demand 
naïve T-cell enrichment kit (Stem cell technologies, 
Canada) including CD14, CD16, CD19, CD20, CD36, 
CD45RO, CD56, CD66b, CD57, CD94, CD123, CD244, 
TCRγ/δ, glycophorin A and dextran-coated magnetic 
particles and according to manufacturer’s instructions.
TSCM, TCM, and TEM were FACS-purified on a FACS 
CANTO II cell sorter (BD Bio- sciences, USA) using 
the fluorescent antibodies anti-CD4, anti-CD8, anti-
CD45RA, anti-CD45RO, anti-CD27, anti-CD95 and 
anti-CCR7.
Primary cells were cultured in RPMI-1640 medium 
supplemented with 10  % heat inactivated fetal bovine 
serum (FBS), penicillin (100  U/ml) and streptomycin 
(100  µg/ml) (ThermoFisher Scientific, USA). All cell 
cultures were performed at 37  °C in a fully humidified 
atmosphere with 5 % CO2 in air.
Purified naïve T cells (higher than 95 %) were activated 
with anti-CD3/CD28 magnetic beads (Life Technologies, 
USA) in 1:2 bead/T-cell ratio, and then cultured with: 
IL-7 and IL-15 at 25 ng/ml each [11] (Peprotech, USA) or 
IL-7, IL-15 and IL-21 at 25 ng/ml each (Peprotech, USA). 
2,5  ×  105 cells/ml per well were plated in a 24-wells 
plate. After day 6, cells were cultured at a concentra-
tion of 1 × 106 cells/ml and plated in 12 or 6-well plates 
(depending on cell number). Cytokines and medium were 
replaced every 3–4  days, and cells were counted every 
3–4 days by Trypan blue dye exclusion.
All donor’s samples were obtained according to a pro-
tocol approved by the Ethics Comittee of Hospital Santa 
Creu I Sant Pau.
Lentivirus production and transduction
A second generation lentival expression vector pLS-CG 
was used to generate GFP-encoding lentivirus. Lentivirus 
was produced in 293T cells cotransfected with the len-
tiviral vector and the packaging vectors pCMV-dR8.91 
and pCMV-G using jet PRIME (Polyplus Transfection). 
Medium was changed 4  h after transfection, and lenti-
virus collected and concentrated after 48–72  h.  Trans-
duction was performed 48  h after initial stimulation by 
1000 g spinoculation for 2 h at 32  °C in the presence of 
polybrene (5 μg/ml) (Sigma-Aldrich, USA). GFP expres-
sion was detected by flow cytometry in TSCM at day 8 of 
culture.
Flow cytometry, and antibodies and intracellular staining
Cells were thawed and labeled with fluorescent anti-
bodies against human CD4-APC-Vio-770 (clone VIT4), 
CD8-Viogreen (clone BW135/80), CD45RA-PerCP-
Vio700 (clone T6D11), CD45RO-PE (clone UCHL1), 
CD27-Vioblue (clone M-T271), CD95-FITC (clone DX2) 
and CCR7-PE-vio770 (clone REA108) (all from Miltenyi 
Biotech, Germany).
For intracellular staining, cells were stimulated with 
50 ng/mL PMA and 1 μg/ml ionomycin (Sigma-Aldrich, 
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USA) during 6  h. Brefeldin 1× (eBioscience, USA) was 
added for the last 4  h. Cells were stained with surface 
antibodies, washed and fixed with BD Cytofix/Cytoperm 
(BD Biosciences, USA), and intracellular staining was 
performed with anti–IL-2, anti-IFN, granzyme-A, and 
perforin specific-antibodies (miltenyiBiotech, Germany). 
All antibodies were titrated before use.
Corresponding isotypes for each antibody were 
used as controls. Cells were analyzed by flow cytom-
etry using a MACS Quant cytometer (Miltenyi Biotech, 
Germany) and the FlowJo version V10 software (Tree-
star, USA). Different T cell subpopulations obtained 
from fresh blood (Fig.  1a) and cultured cells (Fig.  1b) 
were determined by a previous published gating strat-
egy [11] using fluorescence minus one (FMO) controls 
for each antibody (i.e., samples stained with all fluoro-
chromes except the one of interest). Particularly, TSCM 
were identified by a previously described plotting strat-
egy [11]. Briefly, CD4+ and CD8+ cells were sorted 
and a CCR7 against CD45RO plot were used to select 
CCR7+CD45RO− cells in each subpopulation. In these 
cells, we identified CCR7+CD45RO−CD45RA+ cells 
by plotting CCR7 against CD45RA. Then, CD27 was 
used to detect CCR7+CD45RO−CD45RA+CD27+ cells. 
Finally, a plot of CD95 against CCR7 was used to identify 
CCR7+CD45RO−CD45RA+CD27+CD95+ TSCM (Fig. 1).
Statistical analysis
Statistical analysis was performed with GraphPad Prism 
6 (GraphPad Software, USA). Data are shown as the 
mean ± SEM. Differences were tested for statistical sig-
nificance using one-way ANOVA test. A p value  <0.05 
was considered significant.
Results
Short CD3/CD28 costimulation enriches for memory stem T 
cells (TSCM) cultured with IL‑7/IL‑15
To assess whether the length of CD3/CD28 costimulation 
has an impact on the maintenance of the TSCM phenotype 
in  vitro, naïve T cells were cultured with low doses of 
IL-7 and IL-15 and activated with magnetic beads coated 
with anti-CD3/anti-CD28. A short CD3/CD28 costimu-
lation (48 h) was compared to a long stimulus (the entire 
period of cell culture: 10  days) by analyzing individual 
T-cell subsets at different time points. As shown in 
Fig. 2a, while the percentage of CD4+ TSCM at day 4 was 
comparable between both conditions (35.64 ± 5.1 % and 
28.38 ± 6.9 %; p = 0.42), the short CD3/CD28 costimu-
lation led to a significant increase in the frequencies of 
CD4+ TSCM after day 4 that was maintained until the end 
of the culture (34.6 ± 4.4 % vs 15.6 ± 4.24 % respectively; 
p = 0.008) (Fig. 2a).
Similar results were obtained in the CD8+ TSCM pop-
ulation (Fig. 2b). A short costimulation generated a sig-
nificant increase of CD8+ TSCM frequencies compared to 
a long costimulation (20.5 ±  4.00  % vs 7.7 ±  2.53  % at 
day 10, respectively; p = 0.02). Day 10 was selected as an 
endpoint for culture since a decline in TSCM numbers was 
observed after this time (data not shown) and over this 
time period TSCM expand to numbers considered to be 
sufficient for clinical translation.
According to previous data [9], when TSCM are cultured 
in vitro they may also acquire the expression of CD45RO, 
while preserving CD45RA and CCR7+CD27+CD95+ 
expression (i.e., a TSCM-like phenotype). We found no 
differences in the percentage of both CD4+ and CD8+ 
TSCM-like cells across different time points over the 
culture period (19.4 ± 3.06 % vs 24.4 ± 2.6 % in CD4+; 
p = 0.252 and 49.95 ± 3.6 % vs 53.36 ± 1.04 % in CD8+; 
p = 0.35).
When total TSCM (i.e., TSCM  +  TSCM-like popula-
tion) were analyzed (Fig. 2c, d), a higher percentage was 
observed in the CD4+ population after a short stimula-
tion, reaching 54.02 ± 3.837 % at day 10 vs 38.49 ± 1.48 % 
in the long stimulus condition (p  =  0.0054) (Fig.  2c). 
In the CD8+ population, a trend to higher percentages 
were found after short costimulation compared to a long 
costimulation (70.45 ± 4.1 % vs 60.2 ± 3.29 %; p = 0.08) 
(Fig. 2d).
IL‑21 increases the frequencies of TSCM generated 
under short CD3/CD28 costimulation
Next, we analyzed the impact of IL-21 on the in  vitro 
generation and maintenance of TSCM. As shown in 
Fig.  3a, the addition of IL-21 to the culture from day 0 
significantly increased the percentage of CD4+ TSCM 
after a short CD3/CD28 costimulation (47.92 ±  4.10  % 
vs 34.62  ±  4.44  %; p  =  0.006). However, IL-21 had no 
impact on the percentage of CD4+ TSCM cultured under 
long costimulation (21.1  ±  1.31  % vs 15.6  ±  4.24  %; 
p = 0.17) (Fig. 3a). The same hold true for CD8+ TSCM. 
IL-21 significantly increased the percentage of CD8+ 
TSCM cultured under short costimulation (34.15 ± 3.51 % 
vs 20.5  ±  4.005  %; p  =  0.00039) at day 10 of culture, 
while adding IL-21 to the long costimulation condition 
resulted in no significant changes (10.20  ±  2.34  % vs 
7.73 ± 3.27 %; p = 0.14) (Fig. 3b).
Finally, we analyzed if IL-21 could increase the percent-
age of total TSCM (i.e., TSCM + TSCM-like population). At 
day 10, significant higher frequencies were noted in the 
CD4+ subset in the short costimulation in the presence 
of IL-21 (62.92 ± 5.83 % vs 54.02 ± 3.83 %; short + IL-21 
vs short, respectively; p  =  0.025) (Fig.  3c). Although 
the differences between short and long stimulation in 
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the CD8+ subset are enhanced by the addition of IL-21 
(74.15 ± 5.26 % vs 60.2 ± 3.29 %; short + IL-21 vs short 
respectively; p  =  0.04), no significant differences were 
observed in the short stimulation condition by the addi-
tion of IL-21 regarding total TSCM (74.15  ±  5.26  % vs 
70.45 ± 4.13 %; p = 0.56) (Fig. 3d).
IL-21 is a cytokine with action on multiple T cell sub-
sets. To clarify if the short stimulus with IL-21 could 
affect any of the populations present in the culture, dif-
ferent memory T cell subsets were analyzed at day 10 
(Fig. 4). The percentages of central memory T cells were 
34.27 ±  4.13  % vs 26.4 ±  6.9  %; p =  0.95 in CD4+ and 
16.6 ± 8.52 % vs 15.45 ± 9.5 %; p > 0.05 in CD8+ (short 
vs short +  IL-21 respectively). The percentages of effec-
tor memory T cells were 7.97 ± 0.12 % vs 5.54 ± 0.07 %; 
p  >  0.05 in CD4+, and 4.8  ±  0.54  % vs 4.15  ±  0.59  %; 
p  >  0.05 in CD8+ (short vs short +  IL-21 respectively). 
In addition, CD4+/CD8+ TSCM ratio was also analyzed 
to explore the possibility of an overexpansion of CD8+ in 
detriment of CD4+. IL-21 did not preferentially enriched 
Fig. 1 Gating strategy for the identification of human TSCM. T cells were identified by gating on lymphocytes (SSC versus FSC), singlets (FSC‑H versus 
FSC‑A) and live T cells (SSC versus LIVE/DEAD). CD4+ and CD8+ T cells were simultaneously identified with anti‑CD4 and anti‑CD8 antibodies. a 
Gating strategy of fresh blood cells. After gating on CD4+ and CD8+ cells, TCM and TEM subpopulations were identified based on CCR7 and CD45RO 
expression. In the gated CCR7+CD45RO− population, cells expressing CD45RA and CD27 were further analyzed. In this later population (CCR7+CD4
5RO−CD45RA+CD27+), TN and TSCM were identified based on the CD95 expression. TN is defined as CCR7
+CD45RO−CD45RA+CD27+CD95− whereas 
TSCM subpopulation is defined as CCR7
+CD45RO−CD45RA+CD27+CD95+. Red arrows indicate the sequential gating strategy. b Gating strategy of 
10 days culture cells. After gating on CD4+ and CD8+ cells, TCM and TEM subpopulations were identified based on CCR7 and CD45RO expression. 
In the gated CCR7+CD45RO− population, cells expressing CD45RA and CD27 were further analyzed. In this later population (CCR7+CD45RO−C
D45RA+CD27+), TSCM were identified based on the CD95 expression. TSCM subpopulation is defined as CCR7
+CD45RO−CD45RA+CD27+CD95+. 
Similarly, in the gated CCR7+CD45RO+ population, cells expressing CD45RA, CD27 and CD95+ identify a TSCM‑like subpopulation, which is defined 
as CCR7+CD45RO+CD45RA+CD27+CD95+. Red arrows indicate the sequential gating strategy
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for the CD8+ population since the CD4+ cells were 
maintained over the cell culture period in all the con-
ditions tested (CD4+/CD8+ TSCM ratio: 1.03  ±  0.28 vs 
1.34 ±  0.19 for long versus long +  IL-21 costimulation, 
and 0.68 ± 0.14 vs 0.72 ± 0.002 for short vs short + IL-21 
costimulation; p = 0.23).
Short costimulation combined with IL‑21 enhance TSCM 
expansion
Next, we analyzed the effect of IL-21 in TSCM expansion 
under the costimulation conditions described. As shown 
in Fig. 5a, b, the addition of IL-21 to the culture produced 
a significant increase in the TSCM expansion. The combi-
nation of short costimulation and IL-21 led to the greater 
TSCM expansion, for both CD4+ and CD8+ subsets, 
among all conditions tested (CD4+ TSCM: 311.34  ±  39 
fold vs 192.84  ±  58.61 fold; TSCM: 728.06  ±  53 fold 
vs 442.73  ±  122 fold; IL-21 vs no IL-21 respectively; 
p  =  0.040) (Fig.  5a, b). Finally, we analyzed the impact 
of IL-21 on total TSCM expansion. As shown in Fig.  5c, 
d, the combination of short costimulation and IL-21 led 
to the greatest expansion of total CD4+ and CD8+ TSCM 
(351.79  ±  36 fold vs 251.83  ±  16.6 fold; p  =  0.07, and 
744.46 ± 101.76 fold vs 592.3 ± 172 fold; short + IL-21 vs 
long, respectively; p = 0.1) (Fig. 5c, d).
TSCM shows different functional properties
To further define the functional features of T-cells gener-
ated under these conditions, we analyzed the expression 
of IL-2, IFN-γ, granzyme-A and perforin on FACS-puri-
fied TSCM, TCM and TEM at day 10 of culture. We found 
that both CD4+ and CD8+ TSCM secrete higher lev-
els of IL-2 compared to TCM (CD4: 84.65  ±  0.75  % 
vs 83.3  ±  0.7  %; p  =  0.48; CD8: 68.86  ±  1.9  % vs 
62.56 ± 0.13 %, p = 0.03) and TEM (CD4: 84.65 ± 0.75 % 
vs 80.5  ±  0.75  %; p  =  0.057; CD8: 68.86  ±  1.9  % vs 
57.8  ±  1.12  %, p  =  0.0022) (Additional file  1: Figure 
S1 A, B). Moreover, we observed lower proportion of 
CD4+ and CD8+ TSCM that secrete IFN-γ compared 
to TCM (CD4: 8.18 ±  0.16  % vs 13.6 ±  1  %; p =  0.016; 
CD8: 18.66 ±  4.2  % vs 48.76 ±  8.2  %, p =  0.0397) and 
TEM (CD4: 8.18 ± 0.16 % vs 21.55 ± 0.25 %; p = 0.0012; 
CD8: 18.66 ±  4.2  % vs 60.86 ±  6.4  %, p =  0.0091) and 
granzyme-A compared to TCM (CD4: 34.83  ±  8.6  % 
vs 55.66  ±  1.53  %; p  =  0.0631; CD8: 7.2  ±  3.3  % vs 
75.8 ± 0.3 %, p = 0.0004) and TEM (CD4: 34.83 ± 8.6 % 
vs 78.13  ±  2.36  %; p  =  0.0033; CD8: 7.2  ±  3.3  % vs 
78.1 ± 0.5 %, p = 0.0004). We also observed that CD4+ 
and CD8+ TSCM stained mainly negative for perforin 
(0.024  ±  0.002  % and 0.9  ±  0.3  %, respectively) (Addi-
tional file 1: Figure S1 C–H).
Fig. 2 Short CD3/CD28 costimulation increases CD4+ and CD8+ TSCM frequencies compared with long costimulation. Naïve T cells from healthy 
donors (n = 6) were cultured for 10 days with short (48 h) (solid black line) or long (solid grey line) costimulation. a, b Frequency of CD4+ (a) and 
CD8+ (b) TSCM cell subset (mean ± SEM). c, d Frequencies of total TSCM (TSCM + TSCM‑like) CD4+ (c) and CD8+ (d) (mean ± SEM). *p < 0.05; **p < 0.01; 
***p < 0.001
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Fig. 3 IL‑21 enhances CD4+ and CD8+ TSCM frequencies. Naïve T cells from healthy donors (n = 6) were cultured for 10 days with short (solid black 
line) or long (solid grey line) costimulation and in the presence (black dashed line) or absence (grey dashed line) of IL‑21. a, b Frequencies of CD4+ and 
CD8+ TSCM (mean ± SEM) are shown in (a) and (b), respectively. c, d Frequencies of CD4+ and CD8+ Total TSCM (TSCM + TSCM‑like) (mean ± SEM) are 
shown in (c) and (d), respectively. *p < 0.05; **p < 0.01; ***p < 0.001
Fig. 4 Analysis of CD4+ and CD8+ T cell subsets composition. a, b Column graphs showing the relative frequencies (mean ± SEM) of CD4+ (a) and 
CD8+ (b) T cell subsets respectively, for each condition tested (long costimulation, short costimulation, long + IL‑21, and short + IL‑21). TN (T Naïve), 
TCM (T central memory), TEM (T effector memory), TEMRA (T effector memory‑RA+ cells)
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Finally, we analyzed the phenotype and self-renewal 
capacity of FACS-purified TSCM cells after being expanded 
for 10 days. We observed that, in contrast to TCM and TEM 
subsets, both CD4+ and CD8+ TSCM maintained their phe-
notype and proliferative capacity in culture for another 
10 days after sorting. Remarkably, 93 % of the CD4+ and 
88  % of CD8+ T cells displayed a TSCM phenotype after 
20 days in culture with IL-7, IL-15 and IL-21, while TCM 
and TEM largely lost their proliferative capacities and 
became differentiated (Additional file 2: Figure S2).
CD4+ and CD8+ TSCM are efficiently transduced  
by lentiviral vectors
Unlike activated and dividing cells, quiescent T cells are 
less permissive to vector transduction. To assess whether 
TSCM generated under this new conditions could be 
genetically modified for adoptive immunotherapy, an 
encoding-GFP lentivirus was used to transduce TSCM. 
We have analyzed transduction efficiencies (multiplicity 
of infection (m.o.i.) = 1) following stimulation of naïve T 
cells for 48  h with magnetic anti-CD3/CD28 beads and 
IL-7, IL-15 and IL-21. Gene transfer in CD4+and CD8+ 
cells averaged 28 and 19  % respectively. The transduc-
tion efficiency was also analyzed in the different mem-
ory subset presents in the culture. We observed similar 
transduction percentages of TSCM and TCM in both CD4+ 
and CD8+ population (32.25 ± 5.91 % vs 24.30 ± 4.36 % 
in CD4+, TSCM vs TCM respectively; P  =  0.056 and 
21.29 ± 3.54 % vs 17.96 ± 3.07 % in CD8+, TSCM vs TCM 
respectively; p = 0.5;) (Fig. 6).
Discussion
The generation of TSCM for ACT has become a clini-
cally relevant issue since preclinical studies have shown 
that the use of the less-differentiated TSCM is associated 
with superior T-cell engraftment, persistence, and antitu-
mor efficacy [3–6]. Although ACT to treat cancer have 
experimented significant progress in the past few years, 
particularly with the chimeric antigen receptor (CAR) 
approach, improvements on their clinical efficacy are 
clearly needed. Remarkably, although no ACT clinical 
trials with TSCM have been done in cancer patients so 
far, studies in patients with lymphoma receiving CAR-T 
cells showed that the infusion of  >5  % of cells with a 
Fig. 5 IL‑21 enhances CD4+ and CD8+ TSCM expansion. Naïve T cells from healthy donors (n = 3) were cultured for 10 days and fold expansion were 
analyzed in short costimulation (solid black line), long costimulation (solid grey line) short + IL‑21 (black dashed line) and long + IL‑21 (grey dashed 
line) conditions. a, b Absolute fold expansion of CD4+ (a) and CD8+ (b) (mean ± SEM), expressed in increment of cells from the starting culture 
time point is shown. c, d Absolute fold expansion of CD4+ (c) and CD8+ (d) total TSCM (TSCM + TSCM‑like) (mean ± SEM). *p < 0.05; **p < 0.01; 
***p < 0.001
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TSCM phenotype correlated with greater persistence and 
expansion in vivo, properties associated with clinical effi-
cacy [20].
Previous studies have shown that the combination of 
IL-7, IL-15 and CD3/CD28 costimulation led to the gen-
eration of TSCM from naïve T cells [9]. Interestingly, cells 
generated under this condition also express CD45RO, 
which indicates that the combination of prolonged 
CD3/CD28 costimulation with IL-7 and IL-15 induce a 
more differentiated TSCM (TSCM-like) than the originally 
described [9]. This could be related to the stimulation 
through CD3 and CD28, which expands T cells efficiently 
but also causes a drastic change in the cell phenotype, 
including downregulation of CD45RA, CCR7 and CD62L 
[6, 13, 21]. Although both subsets have comparable gene 
expression profiles, it remains to be proven that the 
TSCM-like subset (i.e., those cells expressing CD45RO in 
addition to CD45RA and CCR7) retain similar antitumor 
efficacy than the less differentiated TSCM. In this regard, 
when CAR-T cells were cultured with IL-7/IL-15, only 
the fraction CD45RA+/CCR7+ retained the ability to 
expand after repetitive antigen stimulations [20]. Accord-
ingly, strategies directed to preserve the phenotype of 
TSCM during their ex vivo generation should be regarded 
a clinical priority.
In this study, we show that a very short (48  h) CD3/
CD28 costimulation increases the percentage of TSCM 
within the CD4+ and CD8+ subsets in detriment of a 
more differentiated phenotypes. Moreover, the contribu-
tion of the less differentiated TSCM to the total TSCM fre-
quency is superior in the short costimulation condition 
compared to a long costimulation, in line with the con-
cept that prolonging the CD3/CD28 stimulation in the 
culture is associated with T cell differentiation [21, 22]. 
In our condition, TSCM proliferation was not affected by 
the absence of a prolonged CD3/CD28 signal, suggesting 
that a continued costimulatory signal would not be nec-
essary to promote an efficient ex vivo TSCM expansion in 
the presence of IL-7 and IL-15 [23–25].
The T-cell receptor signal strength impacts on T cell 
expansion and differentiation [26]. Methods for the gen-
eration of effector T cells based on CD3/CD28 stimula-
tion have relied on the use of a high bead:cell ratio (e.g., 
3:1). We observed that a high bead-to-cell ratio reduced 
the frequency of TSCM and did not generate a strong T 
cell proliferative response, a fact that may be associated 
with activation-induced T cell death [21, 27]. In contrast, 
in our hands, a low bead-to-cell ratio (e.g., 1:2) coupled 
to a short costimulation was the best condition for pro-
moting the generation of higher TSCM frequencies while 
maintaining their proliferative capacity. This is in line 
with recent studies showing that low or equal bead:cell 
ratios give the higher yields of T cells when cultured in 
IL-7 and IL-15 [21]. Moreover we observed that the short 
TCR triggering do not reduced the transduction effi-
ciency of TSCM, probably due to the presence of the IL-7, 
IL-15 or IL-21 cytokines, which promote long-term sur-
vival of resting T cells, while maintaining their matura-
tional status [28].
Previous studies have shown that IL-21 synergizes with 
either IL-7 or IL-15 to regulate CD8+ T cell expansion 
and to maintain a memory phenotype [18, 19, 29]. How-
ever, the potential role of IL-21 in the ex vivo generation 
of TSCM has not been described. Here, we show for the 
first time that the addition of IL-21 significantly increases 
the percentage of CD4+ and CD8+ TSCM cultured with a 
short CD3/CD28 stimulation and IL-7/IL-15. Remark-
ably, addition of IL-21 to that condition further increased 
the proliferation rate of TSCM, which translated into an 
increase of absolute numbers of TSCM at the end of the 
culture. Although previous studies have shown that CD3/
CD28 costimulation in combination with IL-7 and IL-15 
promote a substantial increment in TSCM expansion [9], 
the reduction in the length of costimulation and, particu-
larly, the addition of IL-21 produces even higher numbers 
of TSCM that could be sufficient for clinical translation. 
Interestingly, this effect was noted in both CD4+ and 
CD8+ TSCM, and although the proliferation rate was 
greater in the CD8+ subset compared to that in CD4+, it 
is remarkable that the CD4+/CD8+ ratios of TSCM were 
preserved over the culture period.
According to previous studies showing a higher expres-
sion of IL-21 receptor in activated naïve T cells [30], and 
that the effect of IL-21 might depend on the T cell differ-
entiation status [21, 31], we observed that the impact of 
Fig. 6 Analysis of transduction efficiency with a GFP‑expressing 
lentivirus. Lentivirus transduction efficiency measured in CD4+ and 
CD8+ TSCM and TCM subsets by flow cytometry (% of cells expressing 
GFP; mean ± SEM)
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IL-21 was more pronounced in those T cells with a phe-
notype close to naïve T cells, resulting in an enrichment 
of less differentiated TSCM within the total TSCM subset. 
Moreover, we have noticed a higher expression of IL-21R 
in naïve and TSCM cells compared to more differentiated 
T cells subsets (57.5 % of TSCM vs 22 % of TCM in CD4+ 
and 42.6  % of TSCM vs 5  % of TCM in CD8+) (data not 
shown). Interestingly, this difference is more pronounced 
at day 4 of the culture (in particular in CD8+ T cells), 
which could increase the effect of IL-21 in the following 
days.
It has been shown that self-renewal depends on STAT3 
(Signal transducer and activator of transcription 3) sign-
aling cytokines, including IL-6, IL-10 and IL-21, which 
inhibit exhaustion and differentiation of T cell [32]. 
Similarly, T cells expanded in the presence of IL-21 (the 
unique common γ-chain cytokines to sustain STAT3 
activation) prevent the loss of CD45RA, CD62L, CD27, 
and IL-7Rα, increasing the ability of the cell to release 
IL-2 [33, 34]. Interestingly, we noticed that TSCM, TCM 
and TEM cultured in the presence of IL-21 express high 
level of IL-2. In addition, TSCM express low levels of IFN-
γ, granzyme-A and perforin compared to TCM and TEM. 
Thus, TSCM display phenotypic and functional character-
istics of early-differentiated cells.
We also observed that highly purified naïve T cells are a 
more suitable starting population for TSCM generation in 
contrast to the use of “bulk” peripheral blood mononu-
clear cells [10, 20]. The use of purified naïve T cells may 
overcome the variability of this subset observed between 
donors when using whole peripheral blood lymphocytes. 
Another important issue is the potential deleterious 
effect that more differentiated memory T cells present in 
the starting cell population may have on the generation 
of TSCM. Accordingly, in our experience, TSCM are more 
efficiently generated when naïve T cells are used as start-
ing population (data not shown), in line with previous 
data from Bonini´s group [9].
Conclusions
In summary, we demonstrated that when naïve T cells 
are cultured with IL-7 and IL-15, the use of a very short 
CD3/CD28 costimulation enhances CD4+ and CD8+ 
TSCM generation and expansion. Moreover, the addition 
of IL-21 to this culture conditions produces a further 
enrichment and greater expansion of CD4+ and CD8+ 
TSCM. Importantly, the conditions described here allow 
an efficient transduction of both CD4+ and CD8+ TSCM 
with lentivirus. These refinements on the in vitro condi-
tions may be of clinical relevance for the generation of 
TSCM for ACT of patients with cancer, and can be easily 
adapted to preserve this cell subset in the final product 
under GMP conditions.
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